Shanghai Henlius Biotech, Inc. Class H (2696) Price & Analysis

Compare

5 Followers

2696 Stock Chart & Stats

HK$67.55

HK$0.05(0.21%)

At close: Jan 09 4:00 PM EST

HK$67.55

HK$0.05(0.21%)

Day’s Range― - ―

52-Week RangeHK$15.20 - HK$92.00

Previous CloseN/A

Volume849.10K

Average Volume (3M)1.53M

Market Cap

HK$34.13B

Enterprise ValueHK$31.74B

Total Cash (Recent Filing)HK$972.50M

Total Debt (Recent Filing)HK$3.67B

Price to Earnings (P/E)38.3

Beta0.49

Next Earnings

Aug 25, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding163,428,540

10 Day Avg. Volume1,665,497

30 Day Avg. Volume1,532,406

Financial Highlights & Ratios

PEG Ratio0.30

Price to Book (P/B)4.01

Price to Sales (P/S)2.11

P/FCF Ratio29.89

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$110.79

Price Target Upside64.01% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Cash Flow And R&DA global biosimilar franchise is expected to provide meaningful cash flow to drive R&D.

Pipeline ExpansionThe transition is well supported by an expanding pipeline led by key assets HLX43, which emerges as a potential best-in-class pan-tumor PD-L1 ADC poised for global pivotal studies.

Strategic EvolutionHenlius Biotech is strategically evolving from an early mover in biosimilar to a global innovative biopharma.

Bears Say

Shanghai Henlius Biotech, Inc. Class H News

Shanghai Henlius Biotech’s FUTUONING Added to National Drug List

An update from Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) is now available. Shanghai Henlius Biotech,...

14h ago

2696

Shanghai Henlius Biotech Expands Breast Cancer Portfolio Through Avanc Pharma Collaboration

Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has provided an update. Shanghai Henlius Biotech, Inc. has...

4d ago

2696

Shanghai Henlius Biotech Renews Sinopharm Distribution Agreement

Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has shared an announcement. Shanghai Henlius Biotech, Inc. has...

4d ago

2696

Shanghai Henlius Biotech to Hold EGM for Sinopharm Agreement Approval

Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has shared an announcement. Shanghai Henlius Biotech, Inc. has...

4d ago

2696

Shanghai Henlius Biotech’s HLX14 Biosimilar Gains NMPA Acceptance

An announcement from Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) is now available. Shanghai Henlius Biotech,...

6d ago

2696

Shanghai Henlius Biotech’s HLX37 Receives IND Approval for Phase 1 Trials

Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has provided an announcement. Shanghai Henlius Biotech, Inc. announced...

7d ago

2696

Shanghai Henlius Initiates Phase 1 Study of HLX13 for Liver Cancer

Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has shared an update. Shanghai Henlius Biotech, Inc. has...

13d ago

2696

Shanghai Henlius Biotech’s HANSIZHUANG Receives Breakthrough Therapy Designation

Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has issued an update. Shanghai Henlius Biotech, Inc. announced...

18d ago

2696

Shanghai Henlius Biotech’s HLX11 Receives FDA Approval for Breast Cancer Treatment

Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has shared an update. Shanghai Henlius Biotech, Inc. has...

24d ago

2696

Shanghai Henlius Biotech Secures FDA Orphan-drug Designation for HLX43

Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) just unveiled an announcement. Shanghai Henlius Biotech, Inc. announced...

2M ago

2696

2696 FAQ

What was Shanghai Henlius Biotech, Inc. Class H’s price range in the past 12 months?

Shanghai Henlius Biotech, Inc. Class H lowest stock price was HK$15.20 and its highest was HK$92.00 in the past 12 months.

What is Shanghai Henlius Biotech, Inc. Class H’s market cap?

Shanghai Henlius Biotech, Inc. Class H’s market cap is HK$34.13B.

When is Shanghai Henlius Biotech, Inc. Class H’s upcoming earnings report date?

Shanghai Henlius Biotech, Inc. Class H’s upcoming earnings report date is Aug 25, 2025 which is 105 days ago.

How were Shanghai Henlius Biotech, Inc. Class H’s earnings last quarter?

Shanghai Henlius Biotech, Inc. Class H released its earnings results on Mar 24, 2025. The company reported HK$0.867 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.867.

Is Shanghai Henlius Biotech, Inc. Class H overvalued?

According to Wall Street analysts Shanghai Henlius Biotech, Inc. Class H’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Shanghai Henlius Biotech, Inc. Class H pay dividends?

Shanghai Henlius Biotech, Inc. Class H does not currently pay dividends.

What is Shanghai Henlius Biotech, Inc. Class H’s EPS estimate?

Shanghai Henlius Biotech, Inc. Class H’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Shanghai Henlius Biotech, Inc. Class H have?

Shanghai Henlius Biotech, Inc. Class H has 163,428,540 shares outstanding.

What happened to Shanghai Henlius Biotech, Inc. Class H’s price movement after its last earnings report?

Shanghai Henlius Biotech, Inc. Class H reported an EPS of HK$0.867 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.132%.

Which hedge fund is a major shareholder of Shanghai Henlius Biotech, Inc. Class H?

Currently, no hedge funds are holding shares in HK:2696

Shanghai Henlius Biotech, Inc. Class H Stock Smart Score

Outperform

Fundamentals

Return on Equity

27.37%

Trailing 12-Months

Asset Growth

18.00%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Shanghai Henlius Biotech, Inc. Class H

Shanghai Henlius Biotech, Inc. Class H (2696) is a biotechnology company based in Shanghai, China, specializing in the development and commercialization of innovative monoclonal antibody therapies. The company focuses on addressing unmet medical needs in various therapeutic areas, including oncology, autoimmune diseases, and infectious diseases. Henlius aims to enhance patient access to high-quality biologics and is committed to advancing its proprietary drug candidates through rigorous clinical development and regulatory approval processes.

Shanghai Henlius Biotech, Inc. Class H (2696) Earnings & Revenues

Historic Earnings Reports

2696 Stock 12 Month Forecast

Average Price Target

HK$110.79

▲(64.01% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"HK$9","37":"HK$37","65":"HK$65","93":"HK$93","121":"HK$121"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120.87,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$120.87</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":110.79,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$110.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$100.70</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,37,65,93,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"May<br/>2024","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.85,73.77461538461537,77.69923076923077,81.62384615384615,85.54846153846154,89.47307692307692,93.39769230769231,97.32230769230769,101.24692307692308,105.17153846153846,109.09615384615384,113.02076923076923,116.94538461538463,{"y":120.87,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.85,72.99923076923076,76.14846153846153,79.2976923076923,82.44692307692307,85.59615384615384,88.74538461538461,91.89461538461538,95.04384615384615,98.19307692307692,101.34230769230768,104.49153846153845,107.64076923076924,{"y":110.79,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.85,72.22307692307692,74.59615384615384,76.96923076923076,79.34230769230768,81.71538461538461,84.08846153846153,86.46153846153845,88.83461538461538,91.2076923076923,93.58076923076922,95.95384615384616,98.32692307692308,{"y":100.7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.54,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.1,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.78,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.78,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.64,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.18,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.32,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.3,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >